As of 2026-04-08, the EV/EBITDA ratio of Rigel Pharmaceuticals Inc (RIGL) is 4.24. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RIGL's latest enterprise value is 542.36 mil USD. RIGL's TTM EBITDA according to its financial statements is 127.88 mil USD. Dividing these 2 quantities gives us the above RIGL EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 14.0x - 17.1x | 14.4x |
| Forward P/E multiples | 13.4x - 18.7x | 16.3x |
| Fair Price | 96.30 - 137.07 | 109.23 |
| Upside | 235.2% - 377.1% | 280.2% |
| Date | EV/EBITDA |
| 2026-04-07 | 4.24 |
| 2026-04-06 | 4.04 |
| 2026-04-02 | 4.07 |
| 2026-04-01 | 4.06 |
| 2026-03-31 | 4.00 |
| 2026-03-30 | 3.81 |
| 2026-03-27 | 3.82 |
| 2026-03-26 | 3.90 |
| 2026-03-25 | 3.89 |
| 2026-03-24 | 3.87 |
| 2026-03-23 | 3.92 |
| 2026-03-20 | 3.84 |
| 2026-03-19 | 3.86 |
| 2026-03-18 | 3.77 |
| 2026-03-17 | 3.90 |
| 2026-03-16 | 3.93 |
| 2026-03-13 | 3.84 |
| 2026-03-12 | 3.93 |
| 2026-03-11 | 4.03 |
| 2026-03-10 | 4.20 |
| 2026-03-09 | 4.15 |
| 2026-03-06 | 4.26 |
| 2026-03-05 | 4.36 |
| 2026-03-04 | 4.37 |
| 2026-03-03 | 4.86 |
| 2026-03-02 | 5.09 |
| 2026-02-27 | 5.11 |
| 2026-02-26 | 5.25 |
| 2026-02-25 | 5.09 |
| 2026-02-24 | 5.08 |
| 2026-02-23 | 5.04 |
| 2026-02-20 | 5.21 |
| 2026-02-19 | 5.38 |
| 2026-02-18 | 5.25 |
| 2026-02-17 | 5.23 |
| 2026-02-13 | 5.05 |
| 2026-02-12 | 5.03 |
| 2026-02-11 | 5.14 |
| 2026-02-10 | 5.09 |
| 2026-02-09 | 5.06 |
| 2026-02-06 | 5.02 |
| 2026-02-05 | 4.89 |
| 2026-02-04 | 5.14 |
| 2026-02-03 | 5.32 |
| 2026-02-02 | 5.29 |
| 2026-01-30 | 5.13 |
| 2026-01-29 | 5.17 |
| 2026-01-28 | 5.18 |
| 2026-01-27 | 5.47 |
| 2026-01-26 | 5.44 |